Lung Cancer
RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE�) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy (MM-398-01-03-04)
- Details
ClinicalTrials.gov ID:
NCT03088813
Diagnosis Type:
NA
USOR Number:
- Address
4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302